Cardioprotective medication use after renal transplantation

Kyle L. Dawson, Samir J. Patel, David Putney, Wadi N. Suki, A. Osama Gaber

Research output: Contribution to journalArticlepeer-review

5 Scopus citations


Cardiovascular disease is the leading cause of death in renal transplant patients. This study compares the use of cardioprotective medications in adult kidney transplant recipients at a single center with recommendations, which have been validated in the general population. Cardioprotective medication use was retrospectively collected post-renal transplant. Patients were defined as high risk if they had pre-transplant coronary heart disease or equivalent risk. "Optimal" treatment was defined as a patient receiving aspirin, statin, angiotensin-converting enzyme inhibitors/angiotensin receptor blocker, and a beta-blocker according to cardiovascular risk. The percentage of high-risk patients optimally treated at one, three, six, and 12 months was 7.7%, 11.5%, 17.6%, and 18.8%, respectively. Although the use of cardioprotective medications was evident in transplant recipients, opportunities exist to increase the use of optimal cardioprotective regimens after renal transplantation.

Original languageEnglish (US)
JournalClinical Transplantation
Issue number6
StatePublished - Nov 1 2010


  • Cardiovascular disease
  • Drug therapy
  • Kidney transplantation

ASJC Scopus subject areas

  • Transplantation


Dive into the research topics of 'Cardioprotective medication use after renal transplantation'. Together they form a unique fingerprint.

Cite this